@RheumNow video from #ACR22 Opioid use in PsA and SpA patients Discussing abstract 1012 by @AlexisOgdie https://t.co/fKRog1aIkH

Ab1012 #ACR22 @AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS 21% PsA pts on opioids, 27% AS on opioids Opioid users - more co-morbidities, 🚬, worse disease Tended to higher use of anti-rheumatic drugs Higher health care utilizations, medical $$ @RheumNow

CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc

• Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Art…

To propose early intervention in pre-clinical PsA we need to first identify pts! Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool Dvlped 600+ Pso M stiff, PASI, nails, fatigue pain severity Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui

Tapryal et al. Diagnostic delay of >6 months contributes to poor PROs in PsA. @RheumNow #ACR22 Abstr#1507 https://t.co/dkaNhXUAeD https://t.co/6G7X7V1aRI

• Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H

• Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Populat…

Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69

• How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients wit…

Promising results for Izokibep in PsA Ph2 RCT meets primary endpoint at Wk 16 ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO MDA: 5% PBO 42% 40mg 39% 80mg Results observed as soon as wk2 No new safety signal compared to IL17Ai https://t.co/Gilhg5k36b Abs#1597 #ACR22 @RheumNow https://t.co/VvxSRLtkFk

• Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy …